M3/6 is a dual-specificity phosphatase that selectively inactivates JNK/SAPK, with a lesser effect on p38 (HOG kinase) and no effect on extracellular signal-regulated kinase ERK2 [12, 13] . BAF cell lines stably transfected with myc-tagged M3/6 complementary DNA (cDNA) were generated. The expression level of tagged M3/6 in five cell clones was determined by Western blot analysis ( Figure 1a) . Three clones expressed a detectable level of tagged M3/6. Expression of M3/6 had no effect on IL-3-induced ERK2 activation as measured by gel mobility shift (Figure 1b) , supporting previous studies [13] . Stimulation of p38 phosphorylation by supraphysiological levels of IL-3 has been reported [11] . However, we observed only a modest increase in p38 phosphorylation in response to the level of IL-3 required to stimulate proliferation ( Figure 1c ) and M3/6 expression did not affect the level of phosphorylated p38 (Figure 1c ). Previous studies have suggested that M3/6 inactivates p38 to some extent, in addition to inactivating JNK/SAPK [13] . The apparent difference in substrate specificity observed here might be due to differences in the subcellular localization of M3/6, which is nuclear in some cell types but both nuclear and cytosolic in others, or may be due to overexpression of M3/6 in the transient transfection assay used previously [13] . In BAF3 cells expressing M3/6, IL-3-induced activation of JNK/ SAPK was inhibited, as measured by a glutathione S-transferase (GST)-Jun pull-down assay (Figure 1d ). Similar selective inhibition of JNK/SAPK activation was also observed in clones M3/6-3 and M3/6-5 (data not shown). An increase in JNK/SAPK upon IL-3 removal from mast cells has been described [14] ; however, little JNK/SAPK activity was observed two hours after IL-3 removal from BAF3 cells (Figure 1d ).
The death rates of cells expressing various levels of M3/6, following withdrawal of IL-3, were identical (Figure 2a) , demonstrating that JNK/SAPK activity was not required for apoptosis upon IL-3 removal. Ceramide has previously been reported to induce apoptosis by stimulating JNK/SAPK activity [3, 4] . In BAF3 cells, M3/6 also inhibited ceramide-induced JNK/SAPK activity (Figure 2b ). However, M3/6 did not affect induction of apoptosis by ceramide, measured either as appearance of apoptotic cells by flow cytometry (Figure 2c ), or as loss of viability (Figure 2d ). Induction of apoptosis by ceramide was slowed in the presence of IL-3; this protective effect was not inhibited by M3/6 (Figure 2c,d ).
Cells overexpressing M3/6 required higher concentrations of IL-3 for survival ( Figure 3a) ; clone M3/6-1, which expressed the highest level of tagged M3/6, required a 10-fold higher concentration of IL-3 to maintain half-maximal viability compared to control cells. IL-3-stimulated proliferation, measured by Expression of dominant negative forms of JNK/SAPK, or of its upstream activators the kinases ASK1 and SEK1, or of its downstream target c-Jun, blocks apoptosis in response to γ-irradiation, removal of nerve growth factor, treatment with tumour necrosis factor (TNF), heat shock, cisplatin, and ceramide treatment [1] [2] [3] [4] [5] [6] [7] [8] . However, cells from mice lacking SEK1 show normal apoptosis in response to environmental stress [15] , while TNF activates JNK/ SAPK by a signalling pathway that does not result in apoptosis [16, 17] . JNK/SAPK activity has also previously been implicated in cell transformation. JNK/SAPK is activated by the Rac and Cdc42 GTPases, although this activation is not essential for Rac stimulation of proliferation, or cytoskeletal reorganization [18] [19] [20] . JNK/SAPK is constitutively active in T cells transformed by the intracellular parasite Theileria parva [21] and activation of the JNK/SAPK pathway has been shown to be required for cell transformation by both the Bcr-Abl and Tpr-Met oncogenes, using dominant negative mutants of c-Jun or Grb2 [22, 23] . However, the overexpression of dominant negative proteins to block signalling pathways could result in the inhibition of other related pathways. Our system, utilizing a dual-specificity phosphatase to inhibit JNK/SAPK activity, is likely to be much more specific. Using this phosphatase, we show that JNK/SAPK activation is not required for induction of apoptosis by IL-3 removal or ceramide treatment. Also, our data suggest for the first time that JNK/ SAPK activation is required for stimulation of cell proliferation by IL-3. Activation of either Ras or ERK2 alone is not sufficient to stimulate cell proliferation in the absence of IL-3 [24, 25] . JNK/SAPK activation, which requires Ras activation plus an additional signal [26] , is a potential effector step at which Ras and additional tyrosine kinase-dependent pathways might integrate to stimulate proliferation in response to cytokines.
Materials and methods

Cell culture and transfection
BAF3 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum and 5% WEHI-3B cellconditioned medium as a source of IL-3. M3/6 cDNA, fused to a myc epitope tag, was cloned into the vector pBABEpuro [27] . Cells were electroporated with M3/6 plasmid using a Gene Pulser (BioRad) with capacitance extender at 300 V, 960 µF. Single-cell clones were isolated at limiting dilution in 4 µg ml -1 puromycin.
Analysis of cell proliferation and viability
IL-3 was removed by washing twice in medium lacking IL-3. Recombinant murine IL-3 was purchased from R&D Systems and C6-ceramide from Calbiochem. Cell viability was determined by counting total and Trypan Blue-excluding cells on a haemocytometer and cell proliferation by incubating cells for 4 h with 5 µCi ml - 
Analysis of ERK2, JNK/SAPK and p38 activities
Phosphorylated ERK2 was detected by gel mobility shift. Cell lysate (20 µg) was separated on a 15% sodium dodecyl sulphate (SDS)-polyacrylamide gel, transferred to nitrocellulose and probed with ERK2 antiserum (no. 122).
Activated p38 was detected using a phospho-p38-specific antibody (New England Biolabs). Total p38 levels were determined using an antibody to p38 (New England Biolabs).
JNK/SAPK activity was assayed in a pull-down assay. Cell lysate 2% SDS, 10% glycerol, 100 µM DTT, 0.02% bromophenol blue], heated at 100°C for 5 min and analysed on a 10% SDS-polyacrylamide gel. The gel was dried and subjected to autoradiography. JNK/SAPK levels were determined using a JNK/SAPK-specific antibody (New England Biolabs). 
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